Eli Lilly Enters Strategic Research Collaboration with Abbisko Therapeutics, Potential $1.9 Billion in Payments
Summary
Eli Lilly has entered a strategic research collaboration and license agreement with Abbisko Therapeutics, focusing on multiple innovative medicine targets. Under the terms, Abbisko is eligible for payments up to $1.9 billion. This agreement expands Eli Lilly's R&D pipeline and potential future drug development.
At the time of this announcement, LLY was trading at $1,107.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.